Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 10
Submit an article Journal homepage
1,014
Views
3
CrossRef citations to date
0
Altmetric
Commentary

A rational strategy to support approved COVID-19 vaccines prioritization

Javier Burgos-Salcedoa Biomathematics Department, Corporación para la Investigación y la Innovación-CIINAS, Colombia;b Centro de investigaciones, Fundación Universitaria San Mateo, ColombiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1257-4226View further author information
ORCID Icon
Pages 3474-3477 | Received 04 Apr 2021, Accepted 20 Apr 2021, Published online: 11 Jun 2021

References

  • World Health Organization. Coronavirus disease (COVID-19) pandemic. https://covid19.who.int/
  • World Health Organization. Coronavirus disease (COVID-19) pandemic. https://www.covid-19vaccinetracker.org/
  • World Health Organization. Coronavirus disease (COVID-19) pandemic. https://www.who.int/publications/m/item/criteria-for-covid-19-vaccine-prioritization
  • Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2020;21:39–51. doi:10.1016/S1473-3099(20)30831-8.
  • Sadoff J, Le Gars G, Shukarev D, Heerwegh D, Truyers C, De Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I. Interim Results of a Phase 1–2a Trial of Ad26.COV2. S Covid-19 Vaccine. NEJM. 2021. Downloaded from nejm.org on February 7, 2021. doi:10.1056/NEJMoa2034201.
  • Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–92. doi:10.1016/S1473-3099(20)30843-4.
  • Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887–97. doi:10.1016/S0140-6736(20)31866-3.
  • Logunov D, Dolzhikova I, Shcheblyakov D, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 February 2. doi:10.1016/S0140-6736(21)00234-8.
  • Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383:1920–31. doi:10.1056/NEJMoa2022483.
  • Mulligan MJ, Lyke KE, Kitchin N. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–94. doi:10.1038/s41586-020-2639-4.
  • Folegatti P, Katie J, Ewer K, Aley P, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–78. doi:10.1016/S0140-6736(20)31604-4.
  • Barrett J, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, Halkerston R, Hill J, Jenkin D, Stockdale L. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;27:279–88. doi:10.1038/s41591-020-01179-4.
  • Ganter B, Wille R. Formal concept analysis, mathematical foundations. Berlin Heidelberg (Germany): Springer-Verlag; 1999.
  • Bourdon-García R, Burgos-Salcedo J. Formalization of an environmental model using formal concept analysis-FCA. J Physics Conf Series. 2016;738:1–7. doi:10.1088/1742-6596/738/1/012054.
  • Wolff KE. Conceptual control of complex industrial production processes. Adv Knowledge Organ. 1994;4:294.
  • Wolff KE. Conceptual quality control in chemical distillation columns. In: Janssen J, McClean S editors. Applied stochastic models and data analysis. UK: University of Ulster; 1995. p. 652–54.
  • Schank R, Abelson R. Scripts, plans, goals, and understanding: an inquiry into human knowledge structures. NJ: Lawrence Erlbaum Associates, Inc; 1977. p. 246.
  • Burgos-Salcedo J. A comparative analysis of clinical stage 3 COVID-19 vaccines using knowledge representation. medRxiv. Submitted to JMPH. doi:10.1101/2021.03.07.21253082.
  • Klasse PJ, Nixon DF, Moore JP. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in non-human primates and humans. Sci Adv. 2021;7:eabe8065. doi:10.1126/sciadv.abe8065.
  • Amanat F, Krammer F. SARS-CoV-2 Vaccines: status Report. Immunity. 2020;52(4):583–89. doi:10.1016/j.immuni.2020.03.007.
  • Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396(10262):1595–606. doi:10.1016/S0140-6736(20)32137-1.
  • Kaur SP, Gupta V. COVID-19 Vaccine: a comprehensive status report. Virus Res. 2020;288:198114. doi:10.1016/j.virusres.2020.198114.
  • Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28(2):626–39. doi:10.1038/s41418-020-00720-9.
  • https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.